Niche healthcare company GoodRx Holdings (NASDAQ: GDRX) was looking spry and healthy on the stock market Thursday. Investors were happy to take a few doses of it following the company’s release of its latest set of quarterly earnings, and they cranked the price of the shares nearly 12% higher. With that, it trounced the S&P 500 index; this rose marginally on the day by 0.6%.
Prescribing a double dose of beats
GoodRx, which specializes in prescription and telehealth services, saw its revenue rise by almost 3% year-over-year to just under $203 million. Non-GAAP (adjusted) net income also advanced, increasing by 5% to hit $34.4 million, or $0.09. Both results were broadly in line with analyst estimates.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
In terms of revenue composition, GoodRx’s main money-earner — prescription transactions — saw a 2% gain to nearly $149 million. Management attributed this to better per-unit economics and a favorable sales mix. Pharmaceutical manufacturer solutions revenue saw a meaty 17% boost, but this business is relatively small; it brought in just under $29 million for the overall top line.
On the downside, subscription revenue fell by 7% year over year to $21 million. This was because of a decline in subscription plans, which in turn was attributable to the ending of GoodRx’s partnership with supermarket chain operator Kroger.
Guiding for gains
As for guidance, GoodRx left one item unchanged and raised another for its anticipated full-year 2025 performance. It’s sticking to its revenue forecast of $810 million to $840 million for the year, which would represent growth of at least 2% over the 2024 tally.
Management slightly increased the projection for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to $273 million to $287 million. The 2024 result was a bit over $260 million.
It feels realistic to me that GoodRx is expecting continued growth; it has appealing diversification in its revenue streams and its core activity, prescriptions, should only become more compelling with the continued aging of the American population. I can understand why investors are bullish on this company.
Should you invest $1,000 in GoodRx right now?
Before you buy stock in GoodRx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GoodRx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $623,103!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $717,471!*
Now, it’s worth noting Stock Advisor’s total average return is 909% — a market-crushing outperformance compared to 162% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 5, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends GoodRx and Kroger. The Motley Fool has a disclosure policy.
